{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-041035","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2022-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.209203+00:00","generated_at":"2026-06-26T11:49:11.798378+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protagonist Therapeutics appoints Asif Ali as EVP, CFO effective April 18, 2022","bullets":["Asif Ali, 48, appointed EVP, CFO; previously VP Finance & CAO at Theravance Biopharma (2018-2022) and VP Corp Controller at Depomed.","Annual base salary $425,000; eligible for discretionary bonus up to 40% of base salary.","Initial equity grant: option to purchase 82,500 shares (4-yr vest, 1-yr cliff) and 13,750 RSUs (4-yr equal installments).","No family relationships with any executive officer or director; no material interests in reportable transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-041035","json":"https://secwatch.observer/filing/0001104659-22-041035.json","markdown":"https://secwatch.observer/filing/0001104659-22-041035.md","text":"https://secwatch.observer/filing/0001104659-22-041035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922041035/0001104659-22-041035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922041035/tm2210916d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T11:49:11.798378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"81eaf68059","claim":"Asif Ali was appointed as Executive Vice President, Chief Financial Officer at Protagonist Therapeutics, Inc.","evidence_excerpt":"On March 25, 2022, the Board of Directors of Protagonist Therapeutics, Inc. (the “Company”) approved the appointment of Asif Ali, 48, to the position of Executive Vice President, Chief Financial Officer, effective on commencement of Mr. Ali’s employment with the Company (April 18, 2022).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922041035/0001104659-22-041035-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President, Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}